Tag Archives: Pfizer

Study Points to Dramatic Drop In R&D Expenditure

Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Also tagged , , , | 1 Comment

The High Cost of Staying Lean

It’s annual meeting time for Big Pharma — and trimming the fat to deliver more bacon to shareholders is the C suite’s preferred plat du jour. But taking costs out of the business can carry a staggering special supplement charge to the menu, with far more at stake than the economizing equivalent of that McDonald’s […]
Posted in Strategy | Also tagged , , , , | Leave a comment

Pfizer to Acquire King Pharmaceuticals

The merger, announced on Tuesday, will cost Pfizer $3.6 billion. Pfizer and King Pharmaceuticals announced on Tuesday they have entered into a definitive friendly merger agreement. Under the terms, Pfizer will acquire King, a diversified specialty pharmaceutical company based in Tennessee, for $3.6 billion in cash, or $14.25 per share. The company emphasized the deal is […]
Posted in Deals | Also tagged | Leave a comment

Pfizer Ends Sutent Trial

Successful cancer drug Sutent may not be effective in prolonging life for patients with castration-resistant prostate cancer. This week, Pfizer announced that it has ended a Phase III trial of cancer drug Sutent. The drug, which was being tested as a treatment for patients with prostate cancer, has already been approved as a treatment for […]
Posted in News | Also tagged , | 1 Comment

Pfizer and American Kennel Club Team Up For New Research

Pfizer’s Animal Health unit has signed an exclusive deal with the American Kennel Club’s Canine Health Foundation (CHF)—the largest nonprofit worldwide—to fund health research exclusively for canines. This new research partnership names Pfizer Animal Health the sole biopharmaceutical partner of CHF, and begins with Pfizer committing to provide an initial $50,000 over a two-year period. […]
Posted in Deals | Also tagged | Leave a comment
  • Categories

  • Meta